BoP Medicine (02142): Phase II SIRIUS study of human-derived long-acting targeted TSLP antibody HBM9378/WIN378 for COPD treatment has completed dosing in the first group of patients.

Wisdom Financial News APP: Biopharmaceuticals-B (02142) announced that their partner, Windward Bio AG (Windward Bio), has completed the dosing of the first group of patients in the Phase II SIRIUS study for the treatment of Chronic Obstructive Pulmonary Disease (COPD) with HBM9378/WIN378 (also known as SKB378), a fully human super long-acting antibody targeting thymic stromal lymphopoietin (TSLP).